A prospective cohort study of hepatic toxicity after stereotactic body radiation therapy for hepatocellular carcinoma

Radiother Oncol. 2018 Oct;129(1):136-142. doi: 10.1016/j.radonc.2018.02.031. Epub 2018 Mar 13.

Abstract

Purpose: To build and validate multivariate normal tissue complication probability (NTCP) models for radiation-induced hepatic toxicity (RIHT) after stereotactic body radiation therapy (SBRT).

Methods: Eighty-five patients with hepatocellular carcinoma (HCC) in a phase II clinical trial were enroled. A progression of at least 1 or 2 points in the Child-Pugh (CP) score post-SBRT was classified as RIHT (≥1 or ≥2). NTCP models for RIHT (≥1 or ≥2) were developed using logistic regression. Nomograms for each model were formulated. The cut-off point of each independent dosimetric risk factor was obtained using receiver-operating characteristic (ROC) analysis. We used an independent cohort (101 patients) for model validation.

Results: Twenty (23.5%) and 12 (14.2%) patients experienced RIHT (≥1) and RIHT (≥2), respectively. V15, VS10, and pretreatment CP (pre-CP) were the optimal predictors for RIHT (≥1 and ≥2) modelling. V15 ≤33.1% and VS10 ≥416.2 mL for RIHT (≥1), and V15 ≤21.5% and VS10 ≥621.8 mL for RIHT (≥2), were the cut-off points. Four NTCP models and their nomograms were generated. These models and nomograms showed good prediction performance (area under the curve (AUC), 0.83-0.89). Our NTCP model (RIHT ≥2) based on V15 plus pre-CP performed well (AUC = 0.78) in a validation cohort.

Conclusion: V15, VS10, and pre-CP are crucial predictors for RIHT (≥1 and ≥2). Our NTCP models and nomograms were conducive to obtain individual constraints for patients with HCC.

Registration number: ChiCTR-IIC-16008233.

Keywords: Child–Pugh; Hepatic toxicity; Hepatocellular carcinoma; Nomogram; Normal tissue complication probability; Stereotactic body radiation therapy.

Publication types

  • Clinical Trial, Phase II
  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Hepatocellular / radiotherapy*
  • Epidemiologic Methods
  • Female
  • Humans
  • Liver / radiation effects
  • Liver Neoplasms / radiotherapy*
  • Male
  • Middle Aged
  • Radiation Injuries / etiology
  • Radiometry
  • Radiosurgery / adverse effects*
  • Radiotherapy Dosage

Associated data

  • ChiCTR/ChiCTR-IIC-16008233